- Validation of splice variants is an important process in molecular genetics and bioinformatics used to confirm whether genetic variations alter normal RNA splicing. Splice variants are genetic changes that affect the removal of introns and the joining of exons during pre-mRNA processing. These variants may disrupt normal splice donor or acceptor sites, alter branch-point sequences, affect regulatory elements, or create new splice sites. Their effects can include exon skipping, intron retention, alternative splice-site usage, and the production of abnormal transcript isoforms. Validating these effects is essential for understanding gene function, identifying disease-causing mutations, and interpreting genetic variation accurately.
- Splice variants may occur in canonical splice donor and acceptor sequences, which are usually located at the boundaries between exons and introns. The major spliceosome commonly recognizes a 5′ donor site beginning with GU and a 3′ acceptor site ending with AG in RNA. Variants can also occur in the branch-point region, polypyrimidine tract, and exonic or intronic splicing enhancers and silencers. Some variants do not directly affect canonical splice sites but influence the binding of splicing regulatory proteins, including serine/arginine-rich (SR) proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs). These changes may alter the recognition of nearby exons or activate cryptic splice sites.
- The validation process generally begins with the identification and computational assessment of candidate splice variants. Whole-genome sequencing (WGS) and whole-exome sequencing (WES) can identify genetic variants that may affect RNA processing. Variant annotation tools and databases help determine their genomic positions, affected genes, transcript consequences, and potential clinical significance. Resources such as Ensembl VEP, ANNOVAR, SnpEff, RefSeq, ClinVar, and dbSNP support variant annotation and interpretation. Particular attention is given to variants near exon–intron boundaries and those located in known regulatory regions.
- Computational splice prediction is commonly used to prioritize variants for experimental validation. SpliceAI uses deep learning to predict changes in splice-site recognition and can identify potential gains or losses of splice donor and acceptor sites. Other tools, including MaxEntScan, NNSplice, Human Splicing Finder, and Pangolin, evaluate splice-site strength or predict possible splicing consequences. These tools can help identify variants likely to cause exon skipping, intron retention, or cryptic splice-site activation. However, computational predictions are not direct evidence of abnormal splicing and should be interpreted alongside RNA sequencing and experimental results.
- RNA sequencing (RNA-seq) provides direct evidence of how genetic variants affect transcript processing. By examining reads that align across exon–exon junctions, researchers can identify abnormal splice junctions, exon skipping, intron retention, and alternative splice-site usage. Splice-aware aligners such as STAR and HISAT2 support the detection of exon–exon junctions, while tools such as rMATS, MAJIQ, SUPPA2, LeafCutter, and Whippet help identify and quantify alternative splicing events. Comparing RNA-seq data from affected and unaffected samples can reveal whether a candidate variant is associated with a specific abnormal transcript pattern. The tissue used for RNA analysis is important because many genes exhibit tissue-specific expression and splicing.
- Reverse transcription polymerase chain reaction (RT-PCR) is one of the most widely used experimental methods for validating splice variants. In this method, RNA is extracted from relevant biological samples and converted into complementary DNA (cDNA) using reverse transcriptase. PCR primers are designed to amplify the region containing the suspected splicing event, usually with primers located in different exons. The resulting products are separated by agarose gel electrophoresis to identify differences in fragment size. For example, exon skipping may produce a shorter PCR product, whereas intron retention may produce a longer product. RT-PCR can therefore provide direct evidence of abnormal transcript processing.
- Sanger sequencing of RT-PCR products provides additional confirmation of the exact splice junctions. After amplification, the PCR products are sequenced to determine which exons are joined and whether unexpected sequences are present. This method can confirm exon skipping, cryptic splice-site activation, and intron retention at nucleotide resolution. When multiple transcript isoforms are present, individual PCR products may need to be separated or cloned before sequencing to characterize each isoform accurately. Sanger sequencing is particularly useful for confirming novel splice junctions identified through RNA-seq.
- Quantitative PCR (qPCR) can be used to measure the relative abundance of normal and abnormal transcript isoforms. Primers may be designed to target a specific exon–exon junction, an exon included only in the normal transcript, or a junction created by abnormal splicing. This approach helps determine whether a splice variant changes the proportion of a particular transcript. Digital PCR can provide highly sensitive quantification of specific splice isoforms, especially when abnormal transcripts are present at low abundance. However, primer specificity and amplification efficiency must be carefully evaluated.
- Minigene assays are useful when the effects of a genetic variant need to be studied under controlled experimental conditions. A minigene construct contains a selected genomic region, usually including an exon and surrounding intronic sequences, inserted into an expression vector. The normal and variant sequences are introduced into suitable cells, and the resulting RNA transcripts are examined using RT-PCR and sequencing. Differences between the normal and variant constructs can demonstrate whether a particular mutation alters splicing. Minigene assays are especially valuable when the relevant human tissue is unavailable or when a variant’s effects need to be isolated from other genetic and environmental influences. However, these assays may not fully reproduce the natural genomic context, chromatin environment, or tissue-specific splicing regulation.
- Long-read RNA sequencing provides another approach for validating complex splice variants. Technologies such as Pacific Biosciences (PacBio) and Oxford Nanopore Technologies can sequence longer RNA-derived molecules and help characterize complete transcript isoforms. Long reads can reveal combinations of exon skipping, alternative splice sites, intron retention, and alternative transcription start or termination sites within the same transcript. This is particularly useful when short-read sequencing cannot reliably distinguish closely related isoforms. Computational tools such as minimap2, FLAIR, TALON, IsoQuant, and SQANTI3 support long-read transcript alignment, reconstruction, classification, and quality assessment.
- An important consideration in splice-variant validation is the possible involvement of nonsense-mediated mRNA decay (NMD). Some abnormal splice products introduce premature termination codons and are rapidly degraded by this cellular surveillance mechanism. Consequently, an abnormal transcript may be difficult to detect in untreated samples. In selected research settings, inhibition of NMD can help reveal otherwise unstable transcripts and clarify the effects of a variant. However, NMD inhibition may introduce secondary changes in RNA expression and should be interpreted cautiously. The presence of a premature termination codon does not automatically establish that NMD will occur, because transcript structure and the position of the termination codon influence this process.
- Validation also requires determining whether the observed splicing change is genuinely associated with the candidate genetic variant. Comparisons between individuals carrying the variant and suitable controls can provide supporting evidence. When possible, RNA from multiple carriers and non-carriers should be examined. Allele-specific RNA analysis may help establish whether abnormal transcripts originate from the chromosome carrying the variant. Family studies can provide additional evidence by examining whether the variant and associated splicing abnormality are inherited together. Relevant information about transcript expression, tissue specificity, and genetic background should also be considered.
- The interpretation of splice variants often follows the recommendations of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP). The ClinGen Sequence Variant Interpretation Splicing Subgroup has also developed recommendations for incorporating RNA splicing evidence into variant classification. Under the ACMG/AMP framework, functional evidence may contribute to the classification of variants as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. RNA evidence can be particularly important when a variant is predicted to disrupt normal splicing. However, the strength of evidence depends on the experimental design, assay validation, transcript relevance, and the observed molecular consequences. A predicted splice effect alone should not be treated as proof of pathogenicity.
- Several limitations can complicate splice-variant validation. Some genes are expressed only in specific tissues or developmental stages, making relevant RNA samples difficult to obtain. Low-abundance transcripts may be difficult to detect, while alternative isoforms can complicate the interpretation of PCR products. Short-read RNA-seq may fail to resolve complex transcript structures, and minigene assays may not reproduce the natural regulatory environment. In addition, normal tissues may contain naturally occurring alternative splicing events, so an abnormal-looking transcript is not necessarily disease-causing. Combining computational prediction, RNA sequencing, targeted experimental assays, and clinical or phenotypic evidence provides a more reliable assessment.
- Validation of splice variants has important applications in clinical genomics, inherited disease research, cancer genetics, and precision medicine. Confirming the effects of splice-disrupting variants can help explain previously unresolved genetic disorders, improve molecular diagnosis, and identify potential treatment targets. Antisense oligonucleotides (ASOs) may be designed to modify splice-site selection and restore a more functional transcript. Nusinersen treatment for spinal muscular atrophy is an example of a therapy that modifies SMN2 splicing to increase the inclusion of exon 7 and improve production of functional SMN protein.
- In animal genomics and breeding, validation of splice variants can help identify genetic mechanisms underlying economically important traits and inherited disorders. Variants affecting RNA processing may influence growth, muscle development, milk production, reproduction, fertility, disease resistance, metabolism, and environmental adaptation. RNA-seq and targeted RT-PCR can be used to investigate whether candidate variants alter transcript processing in relevant tissues. Combining splice-variant validation with genomic information, quantitative genetics, and phenotypic measurements can improve the identification of functional genetic variants and support more accurate genetic evaluations.
- Validation of splice variants therefore connects computational prediction with direct molecular evidence. Bioinformatics tools help identify candidate variants and predict their potential consequences, while RNA sequencing, RT-PCR, Sanger sequencing, qPCR, minigene assays, and long-read technologies provide experimental confirmation. Integrating these approaches improves the interpretation of genetic variation, strengthens disease diagnosis, and supports the discovery of functional mechanisms in human and animal genomes.